Physician profile
Sitha U Miller
NPI 1205929957
$8,505.56
in general payments reported to CMS, 2019-2025
44 companies · $1,712 in 2025
The $1,712 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $994 · 2020: $573 · 2021: $789 · 2022: $1,377 · 2023: $1,823 · 2024: $1,238 · 2025: $1,712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,772.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,257.89 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $951.37 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $764.96 | 2021-2025 | |
| Novo Nordisk INC | $667.54 | 2019-2025 | Wegovy, Ozempic |
| Abbott Laboratories | $580.76 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Zyla Life Sciences, INC. | $434.25 | 2019 | |
| Amgen INC. | $433.70 | 2019-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $398.38 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $374.97 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $313.83 | 2021-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $283.56 | 2024 | Voquezna |
| Allergan, INC. | $271.92 | 2019-2020 | |
| Pfizer INC. | $270.76 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.65 | 2023-2025 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $137.70 | 2021 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sitha Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.